Journal Articles:
2024
James ND, Pirrie SJ, Liu W, Catto JG, JeffersonK, PatelP, Hughes A, Pope AM, Nanton V, Mintz HP, Knight A, Gallagher J, Bryan RT. Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT. NIHR Health Technology Assessment 28(42) 29-Aug-2024 https://doi.org/10.3310/DEHT5407
2023
V Nanton, (List not in order yet) Hughes AI, Pope AM, Jefferson K, Catto J, Knight A, Gallagher J, Mintz HP, Liu W, Pirrie SJ, Young A, Patel P, RT Bryan & James ND. Boosting and broadening recruitment to UK cancer trials: towards a blueprint for action. BMJ Onc. 2023;2: e000092 doi:10.1136/bmjonc-2023-000092
Mintz HP, Dosanjh A, Parsons H, Hughes A, Pope AM, Jakeman A, Liu W, Pirrie SJ, Brannan R, Hounsome L, Wu H, Sydes M, Carpenter J, Murray M, Ahmed S, Nanton V, Jefferson K, Catto J, Gallagher J, Knight A, Bryan RT, James ND, & Patel P. Making administrative healthcare systems clinical data the future of clinical trials: Lessons from BladderPath. BMJ Oncology 2023;2:e000038. Doi: dx.doi.org/10.1136/bmjonc-2023-000038
Baxter L, Bryan RT, Ward DG, The BladderPath trial management group, et al. Properties of non-coding mutation hotspots as urinary biomarkers for bladder cancer detection. Sci Rep; 13(1):1060. 19-Jan-2023 doi.org/10.1038/s41598-023-27675-4
2022
Ward DG, Baxter L, Ott S, Gordon NS, Want J, Patel p, Piechocki K, Silcock L, Sale C, Zeegers MP, Cheng KK, James ND, Bryan RT & BladderPath TMG. Highly Sensitive and Specific Detection of Bladder Cancer via Targeted Ultra-deep Sequencing of Urinary DNA. Euro Urol Oncol 6(1): 2023, pp 67-75. Published online 8-Apr-2022. doi.org/10.1016/j.euo.2022.03.005
2021
Bryan RT, Liu W, Pirrie SJ, Amir R, Gallagher J, Hughes AI, Jefferson KP, Knight A, Nanton V, Mintz HP, Pope AM, Catto JWF, Patel P & James ND. Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study. Eur Uro Jnl July 2021 (Vol 80 (1)) (https://doi.org/10.1016/j.eururo.2021.02.021)
RT Bryan on behalf of The BladderPath trial management group. Reply to Trey Durdin, Alvin Goh, and Eugene Pietzak. Can an imaging-guided pathway replace the current paradigm for muscle-invasive bladder cancer? Euro Urology 80(1): 10-Jun-2021. doi.org/10.1016/j.eururo.2021.04.034
2020
Mintz HP, Dosanjh A, Hughes A, Jakeman A, James ND, Parsons HM, Pope AM & Patel P. Development and validation of a follow-up methodology for a randomised controlled trial, utilising routine clinical data as an alternative to traditional designs: a pilot study to assess the feasibility of use for the BladderPath trial. Pilot and Feasibility Studies Jnl (31-10-2020) 6:165 (-) Doi: 10.1186/s40814-020-00713-y